You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.
A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.
Under the terms of the deal, MDxHealth and QUT will evaluate and develop the test, which will evaluate abnormal DNA methylation changes.
By analyzing mutations in tumors from a broad swath of tobacco smoke-related cancer types, investigators identified more than two-dozen mutational signatures.
In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.
The firm's PCR-based products for HPV-associated cancers look at DNA methylation at specific genes and include several sample preparation kits.
The kit targets several mRNA biomarkers and is the first in a series of salivary diagnostic kits the firm plans to develop for early-stage disease diagnostics.
Researchers saw high recurrence risk in oropharyngeal carcinoma patients with human papillomavirus type 16 DNA in their spit samples both before and after treatment.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.